REGN - Regeneron Pharmaceuticals Inc Stock Price, Fair Value and News

955.76USD-14.21 (-1.46%)Market Closed

Market Summary

USD955.76-14.21

Market Closed

-1.46%

REGN Alerts

2 major insider sales recently.

REGN Stock Price

View Fullscreen

REGN RSI Chart

REGN Valuation

Market Cap

103.0B

Price/Earnings (Trailing)

26.71

Price/Sales (Trailing)

7.86

EV/EBITDA

22.51

Price/Free Cashflow

21.74

REGN Price/Sales (Trailing)

REGN Profitability

EBT Margin

30.85%

Return on Equity

14.29%

Return on Assets

11.22%

Free Cashflow Yield

4.6%

REGN Fundamentals

REGN Revenue

Revenue (TTM)

13.1B

Rev. Growth (Yr)

-0.54%

Rev. Growth (Qtr)

-8.42%

REGN Earnings

Earnings (TTM)

3.9B

Earnings Growth (Yr)

-11.71%

Earnings Growth (Qtr)

-37.74%

Breaking Down REGN Revenue

Last 7 days

5.7%

Last 30 days

1.8%

Last 90 days

0.9%

Trailing 12 Months

26.5%

How does REGN drawdown profile look like?

REGN Financial Health

Current Ratio

5.27

Debt/Equity

0.07

Debt/Cashflow

2.39

REGN Investor Care

Shares Dilution (1Y)

0.65%

Diluted EPS (TTM)

33.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	13.1B	0	0	0
2023	12.4B	12.7B	13.1B	13.1B
2022	16.5B	14.2B	13.5B	12.2B
2021	9.2B	12.4B	13.5B	16.1B
2020	7.0B	7.4B	7.9B	8.5B
2019	6.6B	6.5B	6.6B	6.6B
2018	6.1B	6.2B	6.4B	6.7B
2017	5.0B	5.2B	5.5B	5.9B
2016	4.4B	4.6B	4.7B	4.9B
2015	3.1B	3.4B	3.8B	4.1B
2014	2.3B	2.5B	2.6B	2.8B
2013	1.6B	1.7B	1.9B	2.1B
2012	565.4M	762.0M	1.1B	1.4B
2011	467.7M	459.7M	456.5M	445.8M
2010	407.8M	433.7M	422.2M	459.1M
2009	0	285.4M	332.3M	379.3M
2008	0	0	0	238.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Regeneron Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	sing george l	sold (taxes)	-826,599	942	-877	-
May 03, 2024	sing george l	acquired	826,660	413	2,000	-
May 01, 2024	mccourt marion	sold	-222,352	889	-250	evp commercial
May 01, 2024	ryan arthur f	sold	-89,960	899	-100	-
Apr 29, 2024	yancopoulos george	gifted	-	-	18,148	bd. co-chair, president & cso
Apr 29, 2024	yancopoulos george	gifted	-	-	-36,296	bd. co-chair, president & cso
Apr 01, 2024	mccourt marion	sold	-241,182	964	-250	evp commercial
Apr 01, 2024	ryan arthur f	sold	-96,253	962	-100	-

Which funds bought or sold REGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Codex Capital, L.L.C.	unchanged	-	484,150	5,534,320	2.70%
May 07, 2024	TECTONIC ADVISORS LLC	reduced	-4.09	35,129	722,830	0.06%
May 07, 2024	Headlands Technologies LLC	reduced	-32.02	-278,410	813,304	0.20%
May 07, 2024	SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC	new	-	1,231,990	1,231,990	0.06%
May 07, 2024	OPPENHEIMER & CO INC	reduced	-15.41	-777,716	9,874,180	0.16%
May 07, 2024	ClariVest Asset Management LLC	unchanged	-	84.00	966	-%
May 07, 2024	TLS Advisors LLC	unchanged	-	20,000	240,000	0.56%
May 07, 2024	O'Dell Group, LLC	sold off	-100	-27,227	-	-%
May 07, 2024	Redwood Wealth Management Group, LLC	unchanged	-	46,815	535,144	0.57%
May 07, 2024	SCHWARTZ INVESTMENT COUNSEL INC	unchanged	-	33,680	384,996	0.01%

Are Funds Buying or Selling REGN?

Are funds buying REGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own REGN

No. of Funds

REGN Alerts

2 major insider sales recently.

Unveiling Regeneron Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.25%	8,838,240	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	capital world investors	4.8%	5,194,729	SC 13G/A
Jan 25, 2024	jpmorgan chase & co	6.7%	7,219,436	SC 13G/A
Jan 25, 2024	jpmorgan chase & co	6.7%	7,219,436	SC 13G/A
Jan 25, 2024	blackrock inc.	8.1%	8,629,707	SC 13G/A
Feb 13, 2023	capital world investors	5.9%	6,315,819	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.15%	8,722,448	SC 13G/A
Feb 03, 2023	blackrock inc.	8.6%	9,166,817	SC 13G/A

Recent SEC filings of Regeneron Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
May 01, 2024	144	Notice of Insider Sale Intent
May 01, 2024	144	Notice of Insider Sale Intent
May 01, 2024	4	Insider Trading
May 01, 2024	4	Insider Trading
Apr 25, 2024	ARS	ARS

Peers (Alternatives to Regeneron Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.8	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.13	14.32	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-46.06	3.89	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

Regeneron Pharmaceuticals Inc News

Latest updates

Regeneron Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-8.4%	3,145	3,434	3,363	3,158	3,162	3,414	2,936	2,897	2,857	2,965	4,952	3,453	5,139	2,529	2,423	2,294	1,952	1,828	1,864	1,744	1,578
Costs and Expenses	-2.8%	2,394	2,461	2,252	2,142	2,215	2,268	1,713	-	1,747	1,707	2,312	1,606	1,791	1,416	1,256	1,241	1,296	1,128	1,188	1,005	1,262
S&GA Expenses	-6.6%	689	738	641	652	601	661	529	-	476	450	560	445	415	406	304	327	348	367	452	304	295
R&D Expenses	6.0%	1,248	1,177	1,075	1,085	1,101	1,043	911	-	794	844	738	665	714	743	657	685	722	584	552	526	886
EBITDA Margin	-3.0%	0.35*	0.36*	0.37*	0.41*	0.41*	0.43*	0.50*	0.49*	0.47*	0.57*	0.60*	0.62*	0.61*	0.51*	0.48*	0.47*	0.47*	0.40*	0.41*	0.37*	0.35*
Interest Expenses	-12.0%	16.00	18.00	18.00	19.00	18.00	17.00	15.00	-	13.00	14.00	14.00	14.00	14.00	15.00	15.00	26.00	10.00	6.00	7.00	8.00	8.00
Income Taxes	-77.5%	-21.30	-12.00	103	115	40.00	128	194	-	111	88.00	274	184	654	138	75.00	156	22.00	44.00	98.00	99.00	32.00
Earnings Before Taxes	-38.9%	701	1,148	1,111	1,083	858	1,325	1,510	-	963	1,061	2,503	1,817	3,753	1,253	1,225	998	919	669	890	769	225
EBT Margin	-3.6%	0.31*	0.32*	0.33*	0.38*	0.37*	0.40*	0.47*	0.47*	0.45*	0.55*	0.58*	0.59*	0.58*	0.48*	0.45*	0.44*	0.44*	0.36*	0.37*	0.33*	0.32*
Net Income	-37.7%	722	1,160	1,008	968	818	1,197	1,316	-	852	974	2,229	1,632	3,099	1,115	1,149	842	897	625	792	670	193
Net Income Margin	-2.3%	0.29*	0.30*	0.30*	0.34*	0.34*	0.36*	0.42*	0.42*	0.40*	0.48*	0.50*	0.52*	0.50*	0.44*	0.41*	0.40*	0.40*	0.33*	0.32*	0.32*	0.32*
Free Cashflow	38.8%	1,513	1,090	1,114	1,022	1,368	1,720	629	564	564	2,102	2,373	3,414	627	669	1,231	-254	943	698	787	557	188

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	3.9%	34,370	33,080	32,163	30,658	30,060	29,215	27,678	27,206	26,349	25,435	23,672	21,486	17,772	17,163	16,084	14,429	15,758	14,805	13,939	13,174	12,855
Current Assets	-3.1%	18,872	19,479	18,635	16,923	16,909	15,884	15,429	15,530	14,306	14,015	13,775	13,338	10,055	9,779	9,098	7,860	8,644	7,689	7,109	6,651	6,929
Cash Equivalents	-4.4%	2,610	2,730	2,152	1,937	3,916	3,106	3,491	3,395	3,346	2,886	3,432	2,072	1,438	2,207	1,573	1,992	2,208	1,630	1,385	1,046	1,709
Inventory	5.2%	2,715	2,581	2,562	2,508	2,425	2,402	2,412	2,219	1,992	1,951	2,054	1,984	2,165	1,917	1,802	1,641	1,481	1,416	1,344	1,317	1,209
Net PPE	-	-	-	-	-	-	-	3,704	3,638	3,556	3,482	3,396	3,359	3,263	3,222	3,138	3,031	2,945	2,890	2,771	2,677	2,613
Liabilities	3.8%	7,379	7,107	7,259	6,640	6,565	6,551	6,239	6,518	6,434	6,666	6,414	6,359	5,795	6,138	5,959	5,371	3,625	3,716	3,435	3,418	3,410
Current Liabilities	4.6%	3,581	3,423	3,599	3,104	3,100	3,141	2,879	3,034	3,008	3,933	3,715	3,732	3,218	2,697	2,338	3,702	2,055	2,097	1,765	1,713	1,511
Long Term Debt	0.0%	1,983	1,983	1,983	1,982	1,982	1,981	1,981	1,981	1,980	1,980	1,980	1,979	1,979	1,979	1,978	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	1,983	1,983	1,982	1,982	1,981	1,981	1,981	1,980	1,980	1,980	1,979	1,979	1,979	1,978	-	-	-	-	-	-
Shareholder's Equity	3.9%	26,991	25,973	24,904	24,018	23,495	22,664	21,439	20,688	19,915	18,769	17,258	15,127	11,977	11,025	10,126	9,057	12,133	11,090	10,504	9,756	9,445
Retained Earnings	2.6%	27,982	27,260	26,101	25,093	24,125	23,307	22,110	20,794	19,942	18,968	16,739	15,107	12,008	10,893	9,744	8,902	8,004	7,380	6,588	5,918	5,725
Additional Paid-In Capital	5.2%	11,943	11,354	11,252	10,889	10,598	9,949	9,518	9,120	8,754	8,088	7,919	7,226	6,888	6,716	6,593	6,263	5,211	4,429	4,388	4,264	4,161
Shares Outstanding	1.0%	108	107	106	107	107	107	107	107	107	106	106	105	105	108	108	110	110	109	109	109	109
Float	-	-	-	-	76,700	-	-	-	62,000	-	-	-	57,065	-	-	-	63,344	-	-	-	32,929	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	38.8%	1,513	1,090	1,114	1,022	1,368	1,720	629	564	2,102	2,373	3,414	627	669	1,231	-254	943	698	787	557	188	897
Share Based Compensation	-4.3%	230	240	204	202	239	232	166	160	167	188	137	146	131	122	101	104	106	134	117	106	108
Cashflow From Investing	-2448.5%	-1,687	-66.20	-496	-2,386	-235	-1,857	192	-413	-1,705	-2,012	-2,438	126	-1,059	-305	-775	1,453	-443	-208	-207	-836	-776
Cashflow From Financing	110.6%	47.00	-446	-407	-614	-322	-247	-725	-101	65.00	-906	385	-118	-366	-305	612	-2,612	336	-345	-11.00	-15.30	120
Buy Backs	-0.7%	298	300	507	723	694	428	913	394	352	855	191	289	324	360	100	5,072	336	247	19.00	-	10.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

REGN Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Revenues	$ 3,145.0	$ 3,162.1
Expenses:
Research and development	1,248.4	1,101.2
Acquired in-process research and development	7.1	56.1
Selling, general, and administrative	689.0	601.1
Other operating expense (income), net	15.3	(0.5)
Total Expenses	2,393.6	2,215.4
Income from operations	751.4	946.7
Other income (expense):
Other (expense) income, net	(34.6)	(70.7)
Interest expense	(16.1)	(18.0)
Total other income (expense)	(50.7)	(88.7)
Income before income taxes	700.7	858.0
Income tax (benefit) expense	(21.3)	40.2
Net income	$ 722.0	$ 817.8
Net income per share - basic (in dollars per share)	$ 6.70	$ 7.64
Net income per share - diluted (in dollars per share)	$ 6.27	$ 7.17
Weighted average shares outstanding - basic (in shares)	107.8	107.1
Weighted average shares outstanding - diluted (in shares)	115.1	114.0
Statements of Comprehensive Income
Net income	$ 722.0	$ 817.8
Other comprehensive income (loss), net of tax:
Unrealized gain on debt securities	3.5	57.2
Gain on foreign currency translation	0.2	0.0
Comprehensive income	725.7	875.0
Net product sales
Revenues:
Revenues	1,761.3	1,668.0
Expenses:
Cost of goods, collaboration and contract manufacturing	240.4	208.4
Collaboration revenue
Revenues:
Revenues	1,266.8	1,378.1
Other revenue
Revenues:
Revenues	116.9	116.0
Cost of collaboration and contract manufacturing
Expenses:
Cost of goods, collaboration and contract manufacturing	$ 193.4	$ 249.1

REGN Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,602.0	$ 2,730.0
Marketable securities	7,917.5	8,114.8
Accounts receivable, net	5,222.2	5,667.3
Inventories	2,714.9	2,580.5
Prepaid expenses and other current assets	414.9	386.6
Total current assets	18,871.5	19,479.2
Marketable securities	6,978.8	5,396.5
Property, plant, and equipment, net	4,225.5	4,146.4
Intangible assets, net	1,058.7	1,038.6
Deferred tax assets	2,764.9	2,575.4
Other noncurrent assets	470.2	444.1
Total assets	34,369.6	33,080.2
Current liabilities:
Accounts payable	671.3	606.6
Accrued expenses and other current liabilities	2,392.9	2,357.9
Deferred revenue	516.7	458.9
Total current liabilities	3,580.9	3,423.4
Long-term debt	1,983.3	1,982.9
Finance lease liabilities	720.0	720.0
Deferred revenue	185.8	126.7
Other noncurrent liabilities	908.5	854.1
Total liabilities	7,378.5	7,107.1
Stockholders' equity:
Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none	0.0	0.0
Additional paid-in capital	11,942.6	11,354.0
Retained earnings	27,982.3	27,260.3
Accumulated other comprehensive loss	(77.2)	(80.9)
Treasury Stock, at cost; 25.8 shares in 2024 and 25.5 shares in 2023	(12,856.7)	(12,560.4)
Total stockholders' equity	26,991.1	25,973.1
Total liabilities and stockholders' equity	34,369.6	33,080.2
Class A Stock
Stockholders' equity:
Common stock	0.0	0.0
Common Stock
Stockholders' equity:
Common stock	$ 0.1	$ 0.1

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

CEO	Dr. Leonard S. Schleifer M.D., Ph.D.
WEBSITE	regeneron.com
INDUSTRY	Biotechnology
EMPLOYEES	12256

Regeneron Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Regeneron Pharmaceuticals Inc? What does REGN stand for in stocks?

REGN is the stock ticker symbol of Regeneron Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Regeneron Pharmaceuticals Inc (REGN)?

As of Wed May 08 2024, market cap of Regeneron Pharmaceuticals Inc is 102.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of REGN stock?

You can check REGN's fair value in chart for subscribers.

What is the fair value of REGN stock?

You can check REGN's fair value in chart for subscribers. The fair value of Regeneron Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Regeneron Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for REGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Regeneron Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether REGN is over valued or under valued. Whether Regeneron Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Regeneron Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REGN.

What is Regeneron Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, REGN's PE ratio (Price to Earnings) is 26.69 and Price to Sales (PS) ratio is 7.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Regeneron Pharmaceuticals Inc's stock?

In the past 10 years, Regeneron Pharmaceuticals Inc has provided 0.131 (multiply by 100 for percentage) rate of return.